References
- Raghu G, Collard HT, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824
- Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;183:431-40
- Nathan SD, Shlobin OA, Weir N, et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 2011;140:221-9
- Rochwerg B, Neupane B, Zhang Y, et al. Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. BMC Med 2016;14:18
- King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011;378:1949-61
- Orphanet [Internet]. Prevalence and incidence of rare diseases: bibliographic data. Orphanet Report Series, Rare Diseases collection. July 2017; Number 1. Available at: http://www.orpha.net/orphacom/cahiers/docs/FR/Prevalence_des_maladies_rares_par_ordre_alphabetique.pdf. [Last accessed 5 October 2017]
- Aravena C, Labarca G, Venegas C, et al. Pirfenidone for idiopathic pulmonary fibrosis: a systematic review and meta-analysis. PLoS One 2015;10:e0136160
- Costabel U, Inoue Y, Richeldi L, et al. Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am J Respir Crit Care Med 2016;193:178-85
- Cottin V, Crestani B, Cadranel J, et al. French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis. Rev Mal Respir 2017;34:900-968
- Balsamo R, Lanata L, Egan CG. Mucoactive drugs. Eur Respir Rev 2010;19:127-33
- The Idiopathic Pulmonary Fibrosis Clinical Research Network. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2093-101
- Cottin V, Schmidt A, Catella L, et al. Burden of idiopathic pulmonary fibrosis progression: a 5-year longitudinal follow-up study. PLoS One 2017;12:e0166462
- Rinciog C, Watkins M, Chang S, et al. A cost-effectiveness analysis of nintedanib in idiopathic pulmonary fibrosis in the UK. Pharmacoeconomics 2017;35:479-91
- Haute Autorité de Santé [Internet]. Avis de la Commission de la Transparence de pirfenidone. 2015. Available at: https://www.has-sante.fr/portail/upload/docs/evamed/CT-13850_ESBRIET_PIC_REEV_Avis3_CT13850.pdf. [Last accessed 5 October 2017]
- Haute Autorité de Santé [Internet]. Avis de la Commission de la Transparence de nintedanib. 2015. Available at: https://www.has-sante.fr/portail/upload/docs/evamed/CT-14162_OFEV_PIC_INS_Avis2_CT14162.pdf. [Last accessed 5 October 2017]
- European Medicines Agency [Internet]. European public assessment report, nintedanib. EMA/724832/2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/003821/WC500182477.pdf. [Last accessed 5 October 2017].
- European Medicines Agency [Internet]. European public assessment report, pirfenidone. EMA/160867/2017. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002154/WC500102979.pdf. [Last accessed 5 October 2017]
- Légifrance [Internet]. Journal officiel de la République française, pirfenidone. 16 octobre 2012. Available at: https://www.legifrance.gouv.fr/jo_pdf.do?id=JORFTEXT000026498557. [Last accessed 5 October 2017]
- European Medicines Agency. Summary of product characteristics, pirfenidone. 11 March 2011. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002154/WC500103049.pdf. [Last accessed 5 October 2017]
- European Medicines Agency [Internet]. European public assessment report, nintedanib. EMA/724832/2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/003821/WC500182477.pdf. [Last accessed 5 October 2017]
- Légifrance [Internet]. Journal officiel de la République française, nintedanib. 19 janvier 2016. Available at: https://www.legifrance.gouv.fr/jo_pdf.do?id÷JORFTEXT000031854168. [Last accessed 5 October 2017]
- European Medicines Agency [Internet]. Summary of product characteristics, nintedaninb. 13 February 2015. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003821/WC500182474.pdf. [Last accessed 5 October 2017]
- Meyer AR, Buhl R, Magnussen H. The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. Eur Respir J 1994;7:431-6
- Behr J, Maier K, Degenkolb B, et al. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med 1997;156:1897-901
- Cottin V, Crestani B, Valeyre D, et al. French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis. From the National Reference and the Competence centers for rare diseases and the Société de Pneumologie de Langue Française. Rev Mal Respir 2013;30:879-902
- Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011;365:1079-87
- Richeldi L, du Bois R, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2071-82
- Boehringer Ingelheim. Summary of clinical efficacy. Nintedanib (BIBF 1120). Ingelheim: Boehringer Ingelheim; 2014. (Data on file)
- Boehringer Ingelheim. Post-hoc analysis, phase III. Nintedanib (BIBF 1120). Ingelheim: Boehringer Ingelheim; 2014. (Data on file)
- Boehringer Ingelheim. Clinical study report. Nintedanib (BIBF 1120). Ingelheim: Boehringer Ingelheim; 2014. (Data on file)
- Boehringer Ingelheim. Post-hoc analysis, phase II. Nintedanib (BIBF 1120). Ingelheim: Boehringer Ingelheim; 2014. (Data on file)
- Chevalier J, de Pouvourville G. Valuing EQ-5D using time trade-off in France. Eur J Health Econ 2013;14:57-66
- Ara R, Brazier JE. Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available. Value Health 2011;14:539-45
- Assurance Maladie [Internet]. Base des médicaments et informations tarifaires. Version 921. 2015. Available at: http://www.codage.ext.cnamts.fr/codif/bdm_it/index.php?p_site=AMELI. Last accessed 5 October 2017
- Assurance Maladie [Internet]. Avenant nationale à la convention n°5. 2014. Available at: http://www.ameli.fr/professionnels-de-sante/pharmaciens/votre-convention/convention-nationale-titulaires-d-officine/avenant-n-5-a-la-convention-nationale_rhone.php. [Last accessed 5 October 2017]
- Assurance Maladie [Internet]. Nomenclature des actes de biologie médicale. Version 42, 2014. Available at: http://www.codage.ext.cnamts.fr/f_mediam/fo/nabm/NABM.pdf. [Last accessed 5 October 2017]
- Assurance Maladie [Internet]. Système national inter-régimes. Activité et prescription des médecins en 2013. Available at: http://www.ameli.fr/l-assurance-maladie/statistiques-et-publications/donnees-statistiques/professionnels-de-sante-liberaux/donneesannuelles/donnees-completes-2012-tableaux-personnalisables.php. [Last accessed 5 October 2017]
- Assurance Maladie [Internet]. Classification commune des actes médicaux. Version 39.10. 2015. Available at: http://www.ameli.fr/fileadmin/user_upload/documents/CCAM_V39.pdf. [Last accessed 5 October 2017]
- Assurance Maladie [Internet]. Liste des Prestations et Produits remboursés par l’Assurance Maladie. 2015. Available at: http://www.ameli.fr/professionnels-de-sante/pedicures-podologues/exercer-au-quotidien/liste-des-produits-et-prestations-lpp_rhone.php. Last accessed 5 October 2017
- Cottin V, Bergot E, Bourdin A, et al. Adherence to guidelines in idiopathic pulmonary fibrosis: a follow-up national survey. ERJ Open Res 2015;1. pii: 00032-2015
- Raghu G, Collard HT, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2015;192:238-48
- Canestaro W, Forrester S, Raghu G, et al. Drug therapy for treatment of idiopathic pulmonary fibrosis: systematic review and network meta-analysis. Chest 2016;149:756-66
- Laurenson S, Sidhu R, Goodall M, et al. NICE guidance on nintedanib for treating idiopathic pulmonary fibrosis. Lancer Respir Med 2016;4:176-7
- Kolb M, Richeldi L, Kimura T, et al. Effect of baseline FVC on decline in lung function with nintedanib in patients with IPF: results from the INPULSIS trials. Poster presented at International Conference of the American Thoracic Society; May 15-20, 2015; Denver, CO
- Cottin V, Crestani B, Kolb M, et al. CVF initiale et effet du nintedanib sur la réduction du déclin de la fonction pulmonaire chez des patients atteints de fibrose pulmonaire idiopathique: résultats des études INPULSIS. Rev Mal Respir 2016;33:A126-A127
- Scottish Medicines Consortium [Internet]. Assessment of nintedanib. Number 1076/15. SMC; 2015. Available at: https://www.scottishmedicines.org.uk/files/advice/nintedanib__Ofev__FINAL_September_2015_Amended_06.10.15_for_website.pdf [Last accessed 5 October 2017]
- NICE [Internet]. Nintedanib for treating idiopathic pulmonary fibrosis. Technology appraisal guidance. 2016. Available at: https://www.nice.org.uk/guidance/ta379/resources/nintedanib-for-treating-idiopathic-pulmonary-fibrosis-82602797638597. [Last accessed 5 October 2017]
- Haute Autorité de Santé [Internet]. Avis d’efficience de pirfenidone. 2015. Available at: http://www.has-sante.fr/portail/upload/docs/application/pdf/2017-03/esbriet_20150203_avis_efficience.pdf. [Last accessed 5 October 2017]
- Benard S, Schmidt A, Catella L, et al. Nintedanib cost-utility in idiopathic pulmonary fibrosis in France. Poster presented at: ISPOR 19th Annual European Congress; Vienna, Austria. November 2016. Available at: https://www.ispor.org/research_pdfs/54/pdffiles/PRS45.pdf. [Last accessed 5 October 2017]
- Yu YF, Wu N, Chuang CC, et al. Patterns and economic burden of hospitalizations and exacerbations among patients diagnosed with idiopathic pulmonary fibrosis. JMCP 2016;22:414-23
- RaDiCo-PID [Internet]. Idiopathic interstitial pneumonia: from infancy to elderly. January 2017. Available at: https://epidemiologie-france.aviesan.fr/epidemiology/records/idiopathic-interstitial-pneumonia-from-infancy-to-elderly/eng-gb. [Last accessed 5 October 2017]
- European Medicines Agency [Internet]. Orphan designation, nintedanib. 3 March 2015. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2013/05/WC500143247.pdf. [Last accessed 5 October 2017]
- European Medicines Agency [Internet]. Orphan designation, pirfenidone. 12 March 2015. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2009/10/WC500006133.pdf. [Last accessed 5 October 2017]
- Haute Autorité de Santé [Internet]. Avis de la Commission de la Transparence de pirfenidone. 2012. Available at: http://www.has-sante.fr/portail/upload/docs/application/pdf/2013-01/esbriet_ct_11398.pdf. [Last accessed 5 October 2017]